Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study

• Main Authors: Mayada M. Samkari (Author), Neda'a S. Bokhari (Author), Raghad Alhajaji (Author), Malaz E. Ahmed (Author), Ahmad Al Raddadi (Author), Alaa K. Bahget (Author), Sarah F. Saleh (Author), Faisal Aljehani (Author), Saud H. Alzahrani (Author), Sarah S. Alsifyani (Author), May M. Samkari (Author), Aisha F. Badr (Author), Mai Alalawi (Author), Khalid Al Sulaiman (Author)
• Format: Book
• Published: Elsevier, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Type 2 Diabetes Mellitus (T2DM) patients are exposed to a 7.5 times higher risk of hypoglycemia while fasting during Ramadan. Relevant diabetes guidelines prioritize the use of SGLT2 inhibitors over other classes. There is a great need to enrich data on their safe and effective use by fa...